T W Synold
Overview
Explore the profile of T W Synold including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
674
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Koczywas M, Frankel P, Synold T, Lenz H, Mortimer J, El-Khoueiry A, et al.
Br J Cancer
. 2014 Oct;
111(12):2268-74.
PMID: 25349975
Background: Eribulin mesylate is a synthetic macrocyclic ketone analogue of Halichondrin B that has demonstrated high antitumor activity in preclinical and clinical settings. This phase I study aimed to determine...
2.
Gutova M, Shackleford G, Khankaldyyan V, Herrmann K, Shi X, Mittelholtz K, et al.
Gene Ther
. 2012 Mar;
20(2):143-50.
PMID: 22402322
Medulloblastoma is a heterogeneous diffuse neoplasm that can be highly disseminated, and is the most common malignant childhood brain tumor. Although multimodal treatments have improved survival rates for patients with...
3.
Portnow J, Frankel P, Koehler S, Twardowski P, Shibata S, Martel C, et al.
Cancer Chemother Pharmacol
. 2011 Aug;
69(2):505-14.
PMID: 21850464
Purpose: The primary objective was to determine the maximum tolerated doses (MTDs) of the combination of bortezomib and temozolomide in patients with solid tumors. The secondary objective was to evaluate...
4.
Stein A, ODonnell M, Synold T, Dagis A, Tsirunyan A, Nademanee A, et al.
Bone Marrow Transplant
. 2010 Dec;
46(9):1256-62.
PMID: 21151180
Patients with poor-risk leukemia have a high relapse rate despite allogeneic transplant. We report on the phase-2 trial of an intensified allogeneic transplant regimen whose aim was tolerable toxicity and...
5.
Morgan Jr R, Synold T, Gandara D, Muggia F, Scudder S, Reed E, et al.
Int J Gynecol Cancer
. 2007 Mar;
17(2):373-8.
PMID: 17362315
The purpose of this study was to estimate the response rate of 26-h continuous infusion cyclosporine A (CSA) combined with carboplatin (CBDCA) and subcutaneous alpha-interferon (IFN), in recurrent ovarian cancer...
6.
Marsh S, Somlo G, Li X, Frankel P, King C, Shannon W, et al.
Pharmacogenomics J
. 2007 Jan;
7(5):362-5.
PMID: 17224914
Paclitaxel is commonly used in the treatment of breast cancer. Variability in paclitaxel clearance may contribute to the unpredictability of clinical outcomes. We assessed genomic DNA from the plasma of...
7.
Shibata S, Pezner R, Chu D, Doroshow J, Chow W, Leong L, et al.
Eur J Surg Oncol
. 2004 Jul;
30(6):650-7.
PMID: 15256240
Aim: We describe the feasibility of combining infusional 5-fluorouracil (5-FU) with intraoperative radiation therapy (IORT). Methods: Patients with surgically resectable locally advanced gastrointestinal cancers were treated concurrently during surgery with...
8.
Aparicio A, Eads C, Leong L, Laird P, Newman E, Synold T, et al.
Cancer Chemother Pharmacol
. 2003 Mar;
51(3):231-9.
PMID: 12655442
Purpose: To identify a dose of the demethylating agent 5-aza-2'-deoxycytidine (DAC) with acceptable side effects, and to study its effect on the methylation patterns of relevant genes in tumor biopsies...
9.
Margolin K, Longmate J, Synold T, Gandara D, Weber J, Gonzalez R, et al.
Invest New Drugs
. 2001 Sep;
19(4):335-40.
PMID: 11561695
Dolastatin-10 is a novel pentapeptide agent originally isolated from the marine mollusk Dolabella auricularia with a mechanism of antitumor activity that involves the inhibition of microtubule assembly. We performed a...
10.
Dussault I, Lin M, HOLLISTER K, Wang E, Synold T, Forman B
J Biol Chem
. 2001 Jul;
276(36):33309-12.
PMID: 11466304
The orphan nuclear receptor SXR coordinately regulates drug clearance in response to a wide variety of xenobiotic compounds. This signaling system protects the body from exposure to toxic compounds; however,...